Skip to main
DNLI
DNLI logo

Denali Therapeutics (DNLI) Stock Forecast & Price Target

Denali Therapeutics (DNLI) Analyst Ratings

Based on 20 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Denali Therapeutics Inc is poised for growth with the imminent filing of its tivi biologics license application (BLA) and anticipated market share gains from 2026, bolstered by synergies from in-house manufacturing capabilities for its transport vehicles. Clinical data demonstrate substantial improvements in liver volume and cognitive function among participants, highlighting the effectiveness of its products, particularly DNL310, which is positioned to outperform existing therapies in the market. Financially, the company's operational expenditures are tracking below estimates, with a reasonable anticipated increase of 10-15% for fiscal year 2025, further indicating sound financial management amidst ongoing advancements in its development pipeline.

Bears say

Denali Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to potential delays or failures in the development and commercialization of its product candidates, which could severely impact business prospects and financial results. The discontinuation of the III dose cohort for Elaprase raises concerns about long-term durability in gene therapy approaches, potentially delaying revenue generation and negatively affecting forecasts. Furthermore, issues related to the deployment of existing monoclonal antibody treatments and the recent net loss reported by the company further underscore the uncertainty surrounding acceptable safety and efficacy endpoints in ongoing clinical trials, amplifying the risks associated with investment in the company.

Denali Therapeutics (DNLI) has been analyzed by 20 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Denali Therapeutics (DNLI) Forecast

Analysts have given Denali Therapeutics (DNLI) a Strong Buy based on their latest research and market trends.

According to 20 analysts, Denali Therapeutics (DNLI) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Denali Therapeutics (DNLI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.